CA 27-29 in patients with breast cancer with pulmonary fibrosis.
By A Mystery Man Writer
Description
A series of 4 patients with breast cancer who have persistent elevation in CA 27.29 are reported, finding that false-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Cancer antigen (CA) 27-29, which is expressed on most carcinoma cells, is a soluble form of glycoprotein MUC1. It is overexpressed in tumors involving glandular epithelial cells, such as breast tumors. Measurement of CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. Although serial determination of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. False-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Herein, we report a series of 4 patients with breast cancer (2 patients with interstitial lung fibrosis and 2 patients with nonspecific fibrotic lung changes) who have persistent elevation in CA 27.29 (normal, <38 U/mL).
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://c5.rgstatic.net/m/4671872220764/images/template/default/profile/profile_default_m.jpg)
CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://i1.rgstatic.net/ii/profile.image/272179694665737-1441904104646_Q64/Zafar-Mahmood-2.jpg)
CA27.29: A valuable marker for breast cancer management. A
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://0.academia-photos.com/attachment_thumbnails/69982886/mini_magick20210920-14352-1d2lsvk.png?1632140656)
PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://www.researchgate.net/publication/236908865/figure/fig4/AS:304573114798082@1449627297350/Figure4-Radiological-characteristics-of-rheumatic-interstitial-lung-disease-Asymmetrical.png)
Radiological characteristics of rheumatic interstitial lung
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://i1.rgstatic.net/publication/319912637_Concordance_analysis_of_paired_cancer_antigen_CA_15-3_and_2729_testing/links/5fbcf29a92851c933f527789/largepreview.png)
Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://doximity-res.cloudinary.com/images/f_auto,q_auto,t_public_profile_photo_320x320/ow1zej16qjxluyvoxf8o/karin-bigman-md-daytona-beach-fl.jpg?noindex=true)
Dr. Mudussara A. Khan, MD, Daytona Beach, FL, Oncologist
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://www.researchgate.net/publication/321752528/figure/tbl1/AS:992609090695171@1613667857405/Malignant-and-Benign-Conditions-Associated-With-Elevated-CA27-29-Levels_Q320.jpg)
PDF) Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://image.oaecdn.com/b07f7464-069e-4ea2-9365-f2abd32ed8b6/2960.fig.6.jpg?as=small&v=6)
A non-toxic approach for treatment of breast cancer and its metastases: capecitabine enhanced photodynamic therapy
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://ars.els-cdn.com/content/image/1-s2.0-S0753332221012749-gr2.jpg)
Current advances in prognostic and diagnostic biomarkers for solid
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://0.academia-photos.com/attachment_thumbnails/72718989/mini_magick20211015-1875-940b0m.png?1634324121)
PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://www.frontiersin.org/files/Articles/1275346/fonc-13-1275346-HTML/image_m/fonc-13-1275346-g001.jpg)
Frontiers Proteomic profiling of formalin-fixed paraffine
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://assets.cureus.com/uploads/figure/file/898283/article_river_de9aab00bc8311eea79ad9108b812455-Screen-Shot-2024-01-26-at-11.19.42-AM.png)
Cureus Vanishing Lung Syndrome: A Case Report and Systematic
![CA 27-29 in patients with breast cancer with pulmonary fibrosis.](https://www.frontiersin.org/files/Articles/717984/fonc-11-717984-HTML/image_m/fonc-11-717984-g001.jpg)
Frontiers Evaluation of Lung Tumor Target Volume in a Large
from
per adult (price varies by group size)